Please assess the completion status of the following clinical trial:

Trial Title: De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic colorectal cancer, histologically proven (on primary tumour and/or metastases)~* Unresectable and non-pretreated metastases~* BRAF wild-type~* Patient considered able to receive 3 lines of chemotherapy~* At least one measurable target lesion \> 1 cm according to RECIST 1.1 (Appendix 4)~* Tumour assessment according to RECIST, performed 4 weeks or less prior to randomization~* Age ≥ 18 years~* WHO performance status ≤ 2 (Appendix 5)~* No major surgery within 4 weeks prior to randomisation. Wound healing must be complete~* Life expectancy greater than 3 months~* Laboratory tests: Neutrophils ≥ 1500/mm3, platelets ≥ 100,000/mm3, haemoglobin \> 9 g/dL~* Creatinine clearance \> 30 mL /min (capecitabine dose modification if the creatinine clearance \< 30-50 mL/min), serum creatinine \< 1.25 x ULN~* Liver function tests: bilirubin \< 1.25 x ULN, AST/ALT \< 5 x ULN~* Women of childbearing age and men (who have sexual relations with women of childbearing age) must agree to use effective contraception without interruption throughout the duration of treatment and for 6 months after the last administration~* Signed informed consent~Exclusion Criteria:~* Patient with a potentially resectable colorectal cancer; i.e. for whom the goal of chemotherapy would be to make all metastases resectable~* Patients with symptomatic metastases~* Patient with aggressive disease and a large tumour volume~* Active gastroduodenal ulcer, wound or bone fracture~* At least one of the following laboratory values: Neutrophils \<1500/mm3, platelets \< 100,000/mm3, haemoglobin \< 9 g/dL, total bilirubin \> 1.5 N, alkaline phosphatase \> 2.5 N (or \> 5 N in case of hepatic involvement), serum creatinine \> 1.5 N, 24 hr proteinuria \> 1 g~* Chronic inflammatory bowel disease, extensive resection of the small bowel~* Clinically significant coronary artery disease or a history of myocardial infraction within the last 6 months. Uncontrolled hypertension while receiving chronic medication~* Abdominal or major extra-abdominal surgical procedure (except diagnostic biopsy) or radiation within 4 weeks before starting treatment~* Previous treatment with an anti-angiogenic or irinotecan~* Known or suspected central nervous system metastasis CNS metastases, or suspected CNS metastases~* Other previous malignancies within 5 years, except for basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix - Peritoneal macro-nodular carcinomatosis~* History of haemoptysis ≥ grade 2 (defined as ≥ 2.5 mL of bright red blood per episode) in the month prior to inclusion~* Known hypersensitivity to any component of bevacizumab or to one of the study treatments~* Active infection requiring intravenous antibiotics at start of treatment~* History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to treatment start~* Pregnant or breastfeeding women~* Concomitant participation in another clinical study involving a drug during the treatment phase and 30 days before starting the study treatment~* Patient unable to undergo medical treatment for geographical, social, psychological or legal reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard arm (escalation strategy - arm A) (Type: ACTIVE_COMPARATOR): LV5FU2 (5 FLUOROURACYL)+avastin. After progression: FOLFIRI + avastin. after the 2nd progression:FOLFOX4 (eloxatine)+ avastin.
- Experimental arm (de-escalation strategy -arm B) (Type: EXPERIMENTAL): (4 cycles of FOLFOXIRI (campto) + avastin and 4 cycles of FOLFIRI + avastin) is followed by maintenance with capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).